Aethlon Medical, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021
February 15, 2022 at 03:46 am IST
Share
Aethlon Medical, Inc. reported earnings results for the third quarter and nine months ended December 31, 2021. For the third quarter, the company reported net loss was USD 2.53 million compared to USD 2.44 million a year ago. Basic loss per share from continuing operations was USD 0.16 compared to USD 0.2 a year ago.
For the nine months, net loss was USD 6.63 million compared to USD 5.62 million a year ago. Basic loss per share from continuing operations was USD 0.46 compared to USD 0.5 a year ago.
Aethlon Medical, Inc. (Aethlon) is a medical therapeutic company focused on developing the Hemopurifier, a clinical-stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections suppression, seed the spread of metastasis and inhibit the benefit of cancer therapies. The Hemopurifier is designed to deplete the presence of circulating tumor-derived exosomes that promote immune suppression. Hemopurifier helps to bind and clear multiple different glycosylated viruses, such as human immunodeficiency virus (HIV), hepatitis C virus (HCV), Dengue, West Nile, multiple strains of influenza, Ebola, Chikungunya, smallpox, monkeypox, multiple herpes viruses, a MERS-CoV related pseudovirus, and others. Hemopurifier is used as a device for two independent indications: the treatment of individuals with advanced or metastatic cancer and the treatment of life threating viruses that are not approved therapies.